Histology and histopathology Vol.28, nº 2 (2013)

Permanent URI for this collection

https://hdl.handle.net/10201/55730

Browse

Browsing Histology and histopathology Vol.28, nº 2 (2013) by Author "Friese, Klaus"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX™ detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8
    (F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología, 2013) Dian, Darius; Lenhard, Miriam; Mayr, Doris; Heublein, Sabine; Karsten, Uwe; Goletz, Steffen; Kuhn, Christina; Wiest, Irmi; Friese, Klaus; Weissenbacher, Tobias; Jeschke, Udo
    y. PankoMab-GEX™ is a novel humanized and glycooptimized antibody, which recognizes a novel specific tumour epitope of MUC1 (TA-MUC1). The aim of this study was to evaluate PankoMab-GEX™ binding to a variety of ovarian cancer specimens (n=156) and to normal ovarian tissue. In addition, PankoMab-GEX™ staining was compared to that of the well-known antiMUC1 antibodies HMFG-1 and 115D8. PankoMabGEX™ showed positive reactivity in serous (100% of cases, mean IRS 8.23), endometrioid (95% of cases, mean IRS 6.40), mucinous (58% of cases, mean IRS 4.17), and clear cell (92% of cases, mean IRS 7.58) carcinomas. In contrast to HMFG-1, healthy ovarian tissue was not recognized by PankoMab-GEX™. Staining with antibody 115D8 was increased with staging. Cytoplasmic PankoMab-GEX™ staining increased with tumour grade, but no correlation was found with staging. Univariate Kaplan-Meier analysis revealed a tendency of reduced survival of patients with high expression of TA-MUC1. The findings are encouraging with respect to a potential use of PankoMab-GEX™ as a new therapeutic antibody for the treatment of ovarian cancer patients.
  • Thumbnail Image
    Publication
    Open Access
    Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer
    (F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología, 2013) Ditsch, Nina; Toth, Bettina; Himsl, Isabelle; Lenhard, Miriam; Ochsenkühn, Robert; Friese, Klaus; Mayr, Doris; Jeschke, Udo
    There is evidence that breast cancer patients suffer from thyroid disorders. However, the relation between thyroid receptor (TR) expression and breast cancer remains unknown so far. Therefore, the aim of this study was an immunohistochemical analysis of TR expression in breast cancer patients. Materials and methods: The expression of the combined antibody TRalpha1 and 2 and TRalpha1 or 2 alone as well as the expression of combined TRbeta1 and 2 and TRbeta1 or 2 alone was investigated with specific monoclonal or polyclonal antibodies in 82 patients. All patients presented with a first diagnosis of sporadic breast cancer. The ABC method was used for staining and staining intensities were analyzed using the IRS score. Results: Both TRalpha and TRbeta were expressed in the nuclei of breast cancer cells. In 24% (28/78) of the slides TRalpha1 and 2 IRS was positive. Immunopositivity for TRalpha1 was found in 55/78 slides, for TRalpha 2 in 54/79 slides (71 and 68%, respectively). The expression of TRbeta1 and 2 showed a positive detection in 33/77 (43%) of the slides, for TRbeta1 it was 43/79 (54%), for TRbeta2 60/76 (79%). Significant correlations of the expression of TRs - especially TRalpha2 - were found with further prognostic histopathological parameters such as tumor size, axillary lymph node involvement, grading and hormone receptor status. Multivariate analysis showed a trend for TRalpha2 as an independent predictor of disease-free and overall survival. Discussion: Our results revealed specific alterations in the expression of TRs - especially of TRalpha2 - in breast cancer patients, suggesting it as a marker with possible prognostic validity.